New hope for tough leukemias: experimental drug LBS-007 enters human testing
NCT ID NCT05756322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called LBS-007 in adults with acute leukemias (AML or ALL) that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can control the disease. About 90 participants will receive the drug in increasing doses to check for side effects and signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
NOT_YET_RECRUITINGTaichung, Taiwan
Contact
-
Hollywood Private Hospital
WITHDRAWNNedlands, Washington, Australia
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300020, China
Contact
-
Jining No.1 People's Hospital
RECRUITINGJining, Shandong, 272011, China
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, Taiwan
Contact
-
National Taiwan University Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
Contact
-
Pindara Private Hospital
COMPLETEDBenowa, Queensland, Australia
-
Q Medical Conselling
WITHDRAWNPerth, Washington, 6009, Australia
-
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
-
The Alfred Hospital
ACTIVE_NOT_RECRUITINGMelbourne, Victoria, Australia
-
The First Affiliated Hospital of Xinxiang Medical University
RECRUITINGXinxiang, Henan, 453100, China
Contact
-
The Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, Australia
Contact
-
The University of Kansas Hospital
RECRUITINGFairway, Kansas, 66205, United States
Contact
-
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
-
Wollongong Private Hospital
COMPLETEDWollongong, New South Wales, Australia